Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
Gynecol Oncol. 2013 Apr;129(1):107-12. doi: 10.1016/j.ygyno.2012.12.028. Epub 2012 Dec 26.
Bowel obstruction is a common pre-terminal event in abdominal/pelvic cancer that has mainly been described in small single-institution studies. We used a large, population-based database to investigate the incidence, management, and outcomes of obstruction in ovarian cancer patients.
We identified patients with stages IC-IV ovarian cancer, aged 65 years or older, in the Surveillance, Epidemiology and End Results (SEER)-Medicare database diagnosed between January 1, 1991 and December 31, 2005. We modeled predictors of inpatient hospitalization for bowel obstruction after cancer diagnosis, categorized management of obstruction, and analyzed the associations between treatment for obstruction and outcomes.
Of 8607 women with ovarian cancer, 1518 (17.6%) were hospitalized for obstruction subsequent to cancer diagnosis. Obstruction at cancer diagnosis (HR=2.17, 95%CI: 1.86-2.52) and mucinous tumor histology (HR=1.45, 95%CI: 1.15-1.83) were associated with increased risk of subsequent obstruction. Surgical management of obstruction was associated with lower 30-day mortality (13.4% in women managed surgically vs. 20.2% in women managed non-surgically), but equivalent survival after 30 days and equivalent rates of post-obstruction chemotherapy. Median post-obstruction survival was 382 days in women with obstructions of adhesive origin and 93 days in others.
In this large-scale, population-based assessment of patients with advanced ovarian cancer, nearly 20% of women developed bowel obstruction after cancer diagnosis. While obstruction due to adhesions did not signal the end of life, all other obstructions were pre-terminal events for the majority of patients regardless of treatment.
肠阻塞是腹部/盆腔癌症常见的终末期前事件,主要在小的单一机构研究中进行了描述。我们使用了一个大型的基于人群的数据库来研究卵巢癌患者阻塞的发生率、管理和结果。
我们在监测、流行病学和最终结果(SEER)-医疗保险数据库中确定了年龄在 65 岁或以上、诊断为 IC-IV 期卵巢癌的患者,并于 1991 年 1 月 1 日至 2005 年 12 月 31 日期间诊断。我们对癌症诊断后因肠阻塞住院的预测因素进行建模,对阻塞的管理进行分类,并分析了阻塞治疗与结果之间的关系。
在 8607 名患有卵巢癌的女性中,有 1518 名(17.6%)在癌症诊断后因阻塞而住院。癌症诊断时的阻塞(HR=2.17,95%CI:1.86-2.52)和粘液性肿瘤组织学(HR=1.45,95%CI:1.15-1.83)与随后阻塞的风险增加相关。阻塞的手术治疗与 30 天死亡率较低相关(接受手术治疗的女性为 13.4%,而接受非手术治疗的女性为 20.2%),但 30 天后的生存率和阻塞后化疗的发生率相同。粘连性起源的阻塞患者的中位阻塞后生存时间为 382 天,其他原因的阻塞患者为 93 天。
在这项对晚期卵巢癌患者的大规模、基于人群的评估中,近 20%的女性在癌症诊断后出现肠阻塞。虽然由于粘连引起的阻塞并没有预示生命的终结,但所有其他阻塞对于大多数患者来说都是终末期前事件,无论治疗如何。